News

Prescient Therapeutics expands PTX-200 testing after fourth complete remission

May 11, 2022

Prescient Therapeutics expands PTX-200 testing after fourth complete remission

Australian biotechnology company Prescient Therapeutics will expand testing of its PTX-200 drug after another patient suffering a deadly blood cancer, relapsed and refractory acute myeloid leukemia (AML), experienced a complete remission.

Australian biotechnology company Prescient Therapeutics will expand testing of its PTX-200 drug after another patient suffering a deadly blood cancer, relapsed and refractory acute myeloid leukemia (AML), experienced a complete remission.

The patient – part of Prescient’s Phase 1b trials – was receiving a 45 mg/m2 dosage of PTX-200 and cytarabine (a chemotherapy drug regularly used to treat AML) and recorded complete remission, though some blood cell types were yet to return to their normal levels.

This is the fourth patient to experience a full remission after being treated with the drug at this dosage, with another patient who received 35 mg/m2 doses experiencing a reduction in their cancer burden (considered a ‘partial response’).

“It’s very satisfying to see another patient with remission in a disease that is so aggressive and fatal,” Prescient CEO Steven Yatomi Clarke said.

“Despite recent advancements AML remains a disease of unmet medical need, and we look forward to advancing this study with the aim of benefitting more AML patients.”

The results pave the way for Prescient to expand its Phase 1b trial cohort by three patients, each at 45 mg/m2 to advance its understanding of safety and efficacy of the drug at this dosage.

Professor Jeffrey Lancet, chair of the department of malignant hematology at Florida’s H. Lee Moffitt Cancer Center and principal investigator in the PTX200 trials, said it was encouraging to see another complete response.

“It was also pleasing to see that this dose level was well tolerated by patients, with no reported dose-limiting toxicities,” he added.

“It is believed that 45 mg/m2 may be a biologically effective dose of PTX-200, therefore we will recruit an additional three patients at this dose level to further investigate dose safety and efficacy in this fragile patient population.”

To stay up to date with the latest Prescient Therapeutics news and announcements, register your details on the Prescient Therapeutics investor centre.

Reach Markets have been engaged by PTX to assist with their investor communications.

Sources:


General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG) including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.

Lombok Property Group

Ideal opportunity for investors in a growing property and tourism market

Leave a comment